• الأردن: 00962781409934 - 00962778455550 - 00962791066457, الإمارات: 00971564999475 - 00971501299947 - 00971564880709
  • الجزائر: 0549996833, تونس: 0021671805607, بريطانيا و أوروبا: 00441902871854 - 00447519398225 - 00447517362128 - 00447519398239
  • تركيا: 00905539440472, أمريكا و كندا: 0017735728151 - 0017736162627 - 0018472850055
  • العراق: 07733000696 - 07733598900

The world's biggest scientific documented health website for the happiness and health of your family, with science and faith we build the balance

97073882

Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum.

Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum.









No. Divisions/Titles for Abstract Details

1 Abstract Title Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum.


2 Abstract Source PloS one, 7, e37648.


3 Abstract Author(s) Friedman, J., Alam, S. M., Shen, X., Xia, S.-M., Stewart, S., Anasti, K., Pollara, J., Fouda, G. G., Yang, G. & Kelsoe, G.


4 Article Affiliation Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States, 2 Department of Immunology, Duke University Medical Center, Durham, North Carolina, United States.


5 Abstract Background: Generation of potent anti-HIV antibody responses in mucosal compartments is a potential requirement of a transmission-blocking HIV vaccine. HIV-specific, functional antibody responses are present in breast milk, and these mucosal antibody responses may play a role in protection of the majority of HIV-exposed, breastfeeding infants. Therefore, characterization of HIV-specific antibodies produced by B cells in milk could guide the development of vaccines that elicit protective mucosal antibody responses.
Methods: We isolated B cells from colostrum of an HIV-infected lactating woman with a detectable neutralization response in milk and recombinantly produced and characterized the resulting HIV-1 Envelope (Env)-specific monoclonal antibodies(mAbs).
Results: The identified HIV-1 Env-specific colostrum mAbs, CH07 and CH08, represent two of the first mucosally-derived anti-HIV antibodies yet to be reported. Colostrum mAb CH07 is a highly-autoreactive, weakly-neutralizing gp140-specific mAb that binds to linear epitopes in the gp120 C5 region and gp41 fusion domain. In contrast, colostrum mAb CH08 is a nonpolyreactive CD4-inducible (CD4i) gp120-specific mAb with moderate breadth of neutralization.
Conclusions: These novel HIV-neutralizing mAbs isolated from a mucosal compartment provide insight into the ability of mucosal B cell populations to produce functional anti-HIV antibodies that may contribute to protection against virus acquisition at mucosal surfaces.


6 Summary These novel HIV-neutralizing mAbs isolated from a mucosal compartment provide insight into the ability of mucosal B cell populations to produce functional anti-HIV antibodies that may contribute to protection against virus acquisition at mucosal surfaces.


7 Article Published Date May 2012.


8 Study Type Invitro.


9 Substances Colostrum.


10 Diseases HIV.


11 Pharmacological Actions anti-HIV.


12 Link https://goo.gl/Hhsqk9








videos balancecure


Share it



Subscribe with our newsletter


Comments

No Comments

Add comment

Made with by Tashfier

loading gif
feedback